We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Antibiotics Could Develop From a DNA Binding Compound

By LabMedica International staff writers
Posted on 13 Jul 2009
A synthetic compound has proved surprisingly effective at binding to the DNA of bacteria, killing them on touch within two minutes. More...


Researchers at the at the University of Warwick (Coventery, United Kingdom) discovered the new compound ([Fe2L3]4+), which is composed of an iron triple helicate with three organic strands wrapped around two iron centers, thus forming a helix which looks cylindrical in shape and neatly fits within the major groove of a DNA helix. When the iron-helicate binds to this major groove, it coils the DNA so that it is no longer available to bind to anything else, and is not able to drive biological or chemical processes. A high positive charge inherent in the compound enhances its ability to bind to DNA, which is negatively charged.

The researchers initially focused on the application of this useful property for targeting the DNA of cancer cells, since it could bind to, coil up, and shut down the cancer cell's DNA, thus killing the cell or stopping it replicate. However, the research team quickly realized that it might also be a very clever way of targeting drug-resistant bacteria; since it operates by targeting DNA; the iron helicate avoids all current resistance mechanisms of multiresistant bacteria such as methillicin resistant Streptococcus aureus (MRSA). Subsequently, they found that [Fe2L3]4+ does indeed have a powerful effect on bacteria; when introduced to two test bacteria (Bacillus subtilis and Escherichia coli), it quickly bound to the bacteria's DNA and killed virtually every cell within two minutes of being introduced (though the concentration required for this is high). The study was published in the June 2009 issue of the International Journal of Antimicrobial Agents.

"We were surprised at how quickly this compound killed bacteria and these results make this compound a key lead compound for researchers working on the development of novel antibiotics to target drug resistant bacteria,” said lead author Professor Alison Rodger, Ph.D., of the department of biophysical chemistry.

The researchers will next try to understand how and why the compound can cross the bacteria cell wall and membranes. They also plan to test a wide range of compounds to search for molecules similar to the iron helicate which posses the same mechanism for action, in collaboration with researchers around the world.

Related Links:
University of Warwick




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.